Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel

3rd September 2008 MUNICH, Germany, September 3 /PRNewswire/ -- A sub-analysis of the TRITON-TIMI 38 clinical trial showed that treatment with prasugrel compared with clopidogrel significantly reduced the risk of new or recurrent heart attacks (7.4 percent vs. 9.7 percent, p<0.0001), regardless of whether the events occurred around the time of an artery-opening procedure known as percutaneous coronary intervention (PCI), or if they occurred spontaneously during the longer-term maintenance phase. The analysis was... more

South America - Pharma Events Confirmed for This Year and 2009

16th July 2008 LONDON, July 16 /PRNewswire/ -- CMPi events for the fast-developing pharma markets of South and Latin America debut next month. Rio de Janeiro will host the twin launch of the CPhI South America pharma ingredients and P-MEC South America pharma machinery and equipment exhibitions on Tuesday 19 - Thursday 21 August. Sao Paulo will then host the 2009 events. The launch exhibitions will be held at Brazil's newest convention facility -- the Centro de Convencoes Sulamerica at Cidade Nova, opened... more

Most viewed

South America - Pharma Events Confirmed for This Year and 2009

Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel